IDEXX Laboratories Statistics
Share Statistics
IDEXX Laboratories has 80.42M
shares outstanding. The number of shares has increased by -1.87%
in one year.
| Shares Outstanding | 80.42M |
| Shares Change (YoY) | -1.87% |
| Shares Change (QoQ) | -1.03% |
| Owned by Institutions (%) | 87.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 58 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.03M, so 3.74% of the outstanding
shares have been sold short.
| Short Interest | 3.03M |
| Short % of Shares Out | 3.74% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 3.73 |
Valuation Ratios
The PE ratio is 38.4 and the forward
PE ratio is 37.67.
IDEXX Laboratories's PEG ratio is
6.51.
| PE Ratio | 38.4 |
| Forward PE | 37.67 |
| PS Ratio | 8.75 |
| Forward PS | 7.9 |
| PB Ratio | 21.37 |
| P/FCF Ratio | 42.72 |
| PEG Ratio | 6.51 |
Financial Ratio HistoryEnterprise Valuation
IDEXX Laboratories has an Enterprise Value (EV) of 34.79B.
| EV / Sales | 8.93 |
| EV / EBITDA | 27.27 |
| EV / EBIT | 37.45 |
| EV / FCF | 43.6 |
Financial Position
The company has a current ratio of 1.31,
with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.31 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 0.77 |
| Debt / FCF | 1.24 |
| Interest Coverage | 36.16 |
Financial Efficiency
Return on Equity is 55.65% and Return on Invested Capital is 33.87%.
| Return on Equity | 55.65% |
| Return on Assets | 26.96% |
| Return on Invested Capital | 33.87% |
| Revenue Per Employee | $354,318.55 |
| Profits Per Employee | $80,715.18 |
| Employee Count | 11,000 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 3.98 |
Taxes
| Income Tax | 221.96M |
| Effective Tax Rate | 20% |
Stock Price Statistics
The stock price has increased by 3.14% in the
last 52 weeks. The beta is 1.52, so IDEXX Laboratories's
price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | 3.14% |
| 50-Day Moving Average | 448.22 |
| 200-Day Moving Average | 450 |
| Relative Strength Index (RSI) | 67.3 |
| Average Volume (20 Days) | 850,588 |
Income Statement
In the last 12 months, IDEXX Laboratories had revenue of 3.9B
and earned 887.87M
in profits. Earnings per share was 10.77.
| Revenue | 3.9B |
| Gross Profit | 2.38B |
| Operating Income | 1.13B |
| Net Income | 887.87M |
| EBITDA | 1.28B |
| EBIT | 1.14B |
| Earnings Per Share (EPS) | 10.77 |
Full Income StatementBalance Sheet
The company has 288.27M in cash and 986.95M in
debt, giving a net cash position of -698.68M.
| Cash & Cash Equivalents | 288.27M |
| Total Debt | 986.95M |
| Net Cash | -698.68M |
| Retained Earnings | 5.33B |
| Total Assets | 3.21B |
| Working Capital | 181.4M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 929M
and capital expenditures -130.92M, giving a free cash flow of 798.08M.
| Operating Cash Flow | 929M |
| Capital Expenditures | -130.92M |
| Free Cash Flow | 798.08M |
| FCF Per Share | 9.68 |
Full Cash Flow StatementMargins
Gross margin is 61.04%, with operating and profit margins of 28.95% and 22.78%.
| Gross Margin | 61.04% |
| Operating Margin | 28.95% |
| Pretax Margin | 28.48% |
| Profit Margin | 22.78% |
| EBITDA Margin | 32.73% |
| EBIT Margin | 28.95% |
| FCF Margin | 20.48% |
